DRI Healthcare Trust T.DHT.UN

Updated Assessment

[retiredcf]

They were questioned following the comments from IA Capital. Naturally I disagree with their final statement because I like to jump on board before the majority of investors become aware. GLTA

Revenues have mostly remained flat quarter-over-quarter for the past year, and its profit margins have remained fairly elevated. Debt levels are low, it generates positive free cash flows, and it has strong cash and equity positions. It pays a decent dividend of 3.6% and forward sales growth is good. It is a smaller cap company with limited history, but most financials look good here. We do not see the company undergoing explosive growth, but it may see modest growth in the low double-digits. Management looks pretty good here, with the Chairman having a long background in senior government roles, president of Coastal Contacts and serves on the board of other public companies. The CEO, Behzad Khosrowshahi, has been transforming the company since the private acquisition of Drug Royalty Corp in 2002, and has previously held senior roles at Future Shop and began his career at Deloitte. We think it looks interesting but would like to give it more time before stepping in here.  (5iResearch)